Abattis Receives US and Taiwan Trademark Approvals for Anti-viral Brand Defenzall™
VANCOUVER, Jan. 16, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has been granted Intl Class 5 Trademark for DefenZall in Taiwan and the USA.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to extend the intellectual property of the company as we grow our brands. This mark will be used to brand our proprietary Anti-Viral Nutraceutical Platform of products which are; DefenZall Daily, DefenZall Immune Support and DefenZall Serious Defense They will be launched through our Canadian distributor Hedley Enterprises, on the Internet and via our Distributor in Hong Kong."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with
capabilities through its wholly owned subsidiaries of producing,
licensing and marketing proprietary ingredients and bio-similar
compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and
Animal Nutrition markets. The company owns the exclusive world wide
rights to the Vertical Designs Advanced Automated Growing Technologies
for these markets. The company also has a deep pipeline of proprietary
products ready for sale in high growth areas of Functional Foods and
Supplements business. For more information, visit the Company's website
at www.abattis.com.
ON BEHALF OF THE BOARD
'Mike Withrow'
Michael Withrow, President & CEO
Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.